Unicycive Therapeutics, Inc. (UNCY) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on September 25, 2024, reporting events as of September 24, 2024. Unicycive Therapeutics, Inc. is a Delaware corporation listed on the Nasdaq Capital Market under the symbol UNCY. The filing addresses the Company's compliance status regarding Nasdaq Listing Rule 5550(b)(2) concerning the minimum market value of listed securities.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the market value of listed securities, which was determined to be $35,000,000 or greater for the 10 consecutive business days ending September 23, 2024.
Material Changes
The primary material change reported is the restoration of compliance with Nasdaq listing requirements. Previously, on July 11, 2024, the Company received notice of non-compliance for failing to maintain a minimum market value of $35,000,000 over a 30-day period. As of September 24, 2024, Nasdaq confirmed the Company has regained compliance based on the market value achieved between September 10 and September 23, 2024.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies beyond the resolution of the listing deficiency. The document confirms the removal of the immediate risk of delisting due to market value non-compliance.
Investor Verification Checklist
- Verify the current market capitalization and share price to ensure continued compliance with the $35,000,000 minimum market value requirement.
- Review the Company's most recent 10-Q or 10-K filings for detailed financial performance data, as this 8-K does not contain revenue or cash flow figures.
- Monitor future Nasdaq communications to confirm no new compliance notices are issued regarding other listing standards.